The uTERTpm ddPCR assay identified 33 cases negative by Uromonitor (30 with C228T or C250T mutations targeted by Uromonitor), whereas Uromonitor identified 4 uTERTpm-negative BC patients (all positive for FGFR3 mutations, not targeted by ddPCR). This evidence concerns the gene FGFR3 and breast cancer.